Asparuhova Maria B, Marti Gabriela, Liu Songkai, Serhan Fatima, Trono Didier, Schümperli Daniel
Institute of Cell Biology, University of Bern, Baltzerstrasse 4, 3012 Bern, Switzerland.
J Gene Med. 2007 May;9(5):323-34. doi: 10.1002/jgm.1027.
The HIV-1 regulatory proteins Tat and Rev are encoded by multiply spliced mRNAs that differ by the use of alternative 3' splice sites at the beginning of the internal exon. If these internal exons are skipped, the expression of these genes, and hence HIV-1 multiplication, should be inhibited. We have previously developed a strategy, based on antisense derivatives of U7 small nuclear RNA, that allows us to induce the skipping of an internal exon in virtually any gene. Here, we have successfully applied this approach to induce a partial skipping of the Tat, Rev (and Nef) internal exons. Three functional U7 constructs were subcloned into a lentiviral vector. Two of them strongly reduced the efficiency of lentiviral particle production compared to vectors carrying either no U7 insert or unrelated U7 cassettes. This defect could be partly or fully compensated by coexpressing Rev from an unspliced mRNA in the producing cell line. Upon stable transduction into CEM-SS or CEM T-lymphocytes, the most efficient of these constructs inhibits HIV-1 multiplication. Although the inhibition is not complete, it is more efficient in combination with another mechanism inhibiting HIV multiplication. Therefore, this new approach targeting HIV-1 regulatory genes at the level of pre-mRNA splicing, in combination with other antiviral strategies, may be a useful new tool in the fight against HIV/AIDS.
HIV-1调节蛋白Tat和Rev由多重剪接的mRNA编码,这些mRNA因在内部外显子起始处使用不同的3'剪接位点而有所差异。如果这些内部外显子被跳过,这些基因的表达以及HIV-1的增殖应该会受到抑制。我们之前基于U7小核RNA的反义衍生物开发了一种策略,该策略使我们能够在几乎任何基因中诱导内部外显子的跳过。在这里,我们成功应用这种方法诱导了Tat、Rev(和Nef)内部外显子的部分跳过。将三种功能性U7构建体亚克隆到慢病毒载体中。与携带无U7插入片段或不相关U7盒式结构的载体相比,其中两种构建体显著降低了慢病毒颗粒产生的效率。在生产细胞系中通过共表达来自未剪接mRNA的Rev,可以部分或完全补偿这种缺陷。在稳定转导至CEM-SS或CEM T淋巴细胞后,这些构建体中最有效的一种抑制了HIV-1的增殖。尽管抑制并不完全,但与另一种抑制HIV增殖的机制联合使用时更有效。因此,这种在mRNA前体剪接水平靶向HIV-1调节基因的新方法,与其他抗病毒策略相结合,可能是抗击HIV/AIDS的一种有用的新工具。